NKTR nektar.com: Price-to-Projected Revenue Ratio

Corporate company logo of Nektar Therapeutics Inc (NKTR)

The forward price-to-sales valuation of Nektar Therapeutics (NKTR) reflects market expectations for a scalable pegylation model, where licensing molecules to Big Pharma generates net income without the overhead of manufacturing plants. Business success is predicated on patent protection and joint research with industry behemoths. Currently, 24.40 represents the latest metric reading, capturing a period of rigorous R&D pipeline renewal following a series of setbacks.

Nektar Therapeutics Inc. - NKTR Market Cap to Future Revenue Ratio (period 07/04/2022 - 11/16/2026)

Analytical breakdowns for Nektar Therapeutics (NKTR)

- current price and projected stock value:
- company stock capitalization data:
Fundamental company analysis:NKTR (Nektar)
Manufactured products of Nektar Corp

Forward P/S measures a company's market value relative to expected sales volume, reflecting investor expectations regarding growth rates. Forward P/S dynamics allow for an assessment of the cost of capital's impact on the asset's capitalization. The metric is calculated as the ratio of the current share price to the projected revenue per share. For Nektar Therapeutics (NKTR), this indicator demonstrates how the market values the potential of their unique polymer conjugate platform.

Key competitors

Forward P/S Multiple ARGX (argenx.com)|BioNTech Group (BNTX) - Market Cap to Future Revenue Ratio|ABIVAX - Forward P/S Multiple|ADMA - Forward P/S Multiple|Protagonist (PTGX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Immunovant Inc|Price-to-Projected Revenue Ratio Kiniksa Pharmaceuticals|Grifols Group (GRFS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Price-to-Projected Revenue Ratio CLDX (Celldex Therapeutics)|Price-to-Projected Revenue Ratio Aurinia Pharma AUPH|Forward Price to Sales BCRX|VERA: Forward Price-to-Revenue Multiple|Forward Price to Sales DNTH (Dianthus Therapeutics)|Pharvaris N.V. (PHVS) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio AbCellera Biologics (ABCL)|TRML (Tourmaline Bio Inc) - Forward P/S Multiple|Market Cap to Projected Revenue PGEN (Intrexon)|Forward Price-to-Revenue Multiple PHAR (Pharming)|Price-to-Projected Revenue Ratio UPB (Upstream Bio Corp)|Price-to-Projected Revenue Ratio Zenas Biopharma, Inc. ZBIO|Market Cap to Expected Sales Ratio immunome.com (IMNM)|Gossamer Bio Inc - Forward P/S Multiple|Forward Price to Sales KALV (KalVista Pharmaceuticals, Inc.)|SEPN: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pieris Pharmaceuticals Inc|Forward Price-to-Revenue Multiple SVRA|Forward Price-to-Revenue Multiple Rigel Pharmaceuticals (RIGL)|Forward P/S Multiple ANAB|ATXS - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio enGene Corp ENGN|Market Cap to Expected Sales Ratio RAPT Therapeutics, Inc. (RAPT)|Aerovate - Forward P/S Multiple|ACRS - Forward P/S Multiple|KYTX (Kyverna Therapeutics) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Tiziana Life Sciences Ltd. (TLSA)|Forward Price-to-Revenue Multiple CABA|Ventyx Biosciences (VTYX) - Market Cap to Expected Sales Ratio|Forward P/S Multiple THTX|AVTX (Avalo Therapeutics, Inc) - Forward Price to Sales|Forward P/S Multiple ELDN (eledon.com)|AGEN - Forward Price-to-Revenue Multiple|CLYM - Price-to-Projected Revenue Ratio|Future Price to Revenue ZURA|ATYR: Forward P/S Multiple|Adagene Corp (ADAG) - Forward P/S Multiple|Forward Price-to-Revenue Multiple IMA|Shattuck Labs, Inc. - Future Price to Revenue|Price-to-Projected Revenue Ratio Equillium Inc (EQ)|Forward P/S Multiple Connect Biopharma Holdings (CNTB)|Price-to-Projected Revenue Ratio Immunic, Inc. IMUX|Forward P/S Multiple Atara Biotherapeutics ATRA|IFRX - Price-to-Projected Revenue Ratio|XFOR: Price-to-Projected Revenue Ratio|ACET: Forward P/S Multiple|CELU - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio inmunebio.com|Market Cap to Projected Revenue BRNS (barinthusbio.com)|Forward P/S Multiple KZR|Forward P/S Multiple SAB Biotherapeutics, Inc (SABS)|Forward P/S Multiple AKTX (Akari Therapeutics, Plc)|Forward P/S Multiple enlivex.com ENLV|QTTB: Forward Price-to-Revenue Multiple|GOVX - Forward P/S Multiple|Edesa Biotech Inc (EDSA) - Price-to-Projected Revenue Ratio|IBIO - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio carismatx.com|XTLB: Forward Price to Sales|Price-to-Projected Revenue Ratio Bolt Biotherapeutics Inc. (BOLT)|HCW Biologics - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio aptevotherapeutics.com APVO|AIM - Forward Price-to-Revenue Multiple|Aditxt - Forward P/S Multiple|Market Cap to Expected Sales Ratio GRI Bio Corporation GRI|xortx.com (XRTX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio reshapelifesciences.com (HIND)|Price-to-Projected Revenue Ratio Revelation Bio|Market Cap to Future Revenue Ratio Indaptus Therapeutics, Inc. INDP|Price-to-Projected Revenue Ratio BiondVax Pharmaceuticals (SCNI)|Forward Price-to-Revenue Multiple CalciMedica CALI|Price-to-Projected Revenue Ratio Affimed AFMD|ALLK - Forward Price-to-Revenue Multiple|HOOKIPA Pharma, Inc. - Forward P/S Multiple|Forward Price to Sales IGMS (igmbio.com)|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|Ocean Biomedical Corp (OCEA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Forward P/S Multiple thirdharmonicbio.com